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Background: Bartonella henselae is transmitted amongst cats by Ctenocephalides felis and is associated with
multiple clinical syndromes in cats and people. In a previous study, monthly spot-on administration of 10%
imidacloprid/1% moxidectin was shown to block transmission of B. henselae amongst cats experimentally exposed
to infected C. felis. The purpose of this study was to determine whether application of a flea and tick collar
containing 10% imidacloprid and 4.5% flumethrin would lessen C. felis transmission of B. henselae amongst cats for
8 months.
Methods: Specific pathogen free cats (n = 19) were housed in three adjoining enclosures that were separated by
mesh to allow C. felis to pass among groups but prevent cats in different enclosures from contacting one another.
One group of 4 cats was inoculated intravenously with B. henselae and after infection was confirmed in all cats
based on positive PCR assay results, the cats were housed in the middle enclosure. The B. henselae infected cat
group was flanked by a group of 8 cats that had the collar placed and maintained for the duration of the study
and a group of 7 cats that were not treated. Ctenocephalides felis (50 males and 50 females) raised in an insectary
were placed on each of the 4 cats in the B. henselae infected group monthly for 7 applications and then every 2
weeks for 4 applications starting the day the collar was applied. Blood was collected from all cats weekly for
Bartonella spp. PCR, serology and culture.
Results: While side-effects associated with the collars were not noted, persistent fever necessitating enrofloxacin
therapy occurred in two of the untreated cats. While B. henselae infection was ultimately confirmed in 4 of 7 of the
untreated cats, none of the cats with collars became infected (P = 0.026).
Conclusions: In this study design, use of a collar containing 10% imidacloprid and 4.5% flumethrin was well
tolerated and prevented C. felis transmission of B. henselae amongst cats for 8 months.
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Bartonella henselae is transmitted amongst cats by
Ctenocephalides felis and is associated with multiple
clinical syndromes in cats and people [1-7]. In addition,
Bartonella koehlerae and Bartonella clarridgeiae have
commonly been cultured or amplified from fleas, cats,
and people. Being scratched by a young cat is a major* Correspondence: mlappin@colostate.edu
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reproduction in any medium, provided the orrisk factor for development of bartonellosis in people.
Bartonella henselae is passed in C. felis frass and lives
outside the body for 9 days or longer [8]. It is possible
that the combination of C. felis and the grooming be-
havior of cats leads to Bartonella spp. contamination of
claws. In one study of cats housed in shelters in Florida
and Alabama with high risk for C. felis infestation, DNA
of Bartonella spp. was amplified from the claws of 9 of
51 cats (17.6%) [6].
Use of flea control products that lessen transmission of
Bartonella spp. amongst cats by C. felis may indirectlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ous study, monthly spot-on administration of 10%
imidacloprid/1% moxidectina was shown to block
transmission of B. henselae amongst cats experimen-
tally exposed to infected C. felis [7]. However, this product
is licensed for monthly use and so owner compliance may
be less than 100%. A flea and tick collar containing 10%
imidacloprid and 4.5% flumethrinb was recently registered
in the European Union and the United States [9-11]. This
collar has been shown to be safe for use in kittens > 10
weeks of age and is very effective for the prevention of
fleas and ticks for 8 months which could be very conveni-
ent for some cats and their owners [9-11].
The purpose of this study was to determine whether
application of a flea and tick collar containing 10%
imidacloprid and 4.5% flumethrin to cats would lessen
C. felis transmission of B. henselae amongst cats over an
8 month study period.
Methods
Bartonella henselae isolate
Bartonella henselae strain CSU-1 was initially isolated
from a shelter cat in Florida and has been passaged once
in cats [7]. Blood in EDTA from a cat infected with
CSU-1 by exposure to infected C. felis had been stored
at −80°C until used in the current study.
Ctenocephalides felis
The C. felis used in this study were purchased from an
insectary of a local research laboratory.c Two groups of 5
male and 5 female adult C. felis that were not exposed to
the cats were purchased (one group before the study began
and another group after the completion of this study) and
were pooled by group, subjected to total DNA extraction,
and shown to be negative for DNA of Bartonella spp. and
haemoplasmas by PCR assay [6,11,12].
Flea and tick collar
A flea and tick collar that contains imidacloprid 10%
and flumethrin 4.5% was placed on designated cats in
this study following the manufacturer’s guidelines [9-11].
bThe collars were stored in a locked, fireproof cabinet
and maintained at 20°C to 25°C until used.
Animals
A total of 19 cats (10 male; 9 female) were purchased from
a commercial research cattery at approximately 4 months
of age and shipped to the study site. The cats had been
vaccinated against feline viral rhinotracheitis, feline
calicivirus, and feline panleukopenia virus. During the 49
day equilibration period for the study, the male cats were
neutered following protocols of the animal facility, all cats
were shown to have negative serum test results for FeLV-
antigen, FIV-antibody, Dirofilaria immitis antigen,d andBartonella spp. antibody (ELISA), and all cats were shown
to be negative for Bartonella spp and haemoplasma DNA
in blood using previously reported PCR assays [12-14]. A
temperature sensing microchip was implanted as previ-
ously described for use during clinical monitoring over
the course of the study [15].Experimental design
The study design was approved by the Institutional
Animal Care and Use Committee at the research facilitye
that housed the cats during the flea infestation portion of
the study and the Animal Care and Use Committee at
Bayer Animal Health.
After arrival at the facility and entry into the 49 day
equilibration period, the cats were randomized into 3
groups and housed together in 1 room that was divided
into 3 sections (R1, R2, and R3) beginning on Day −44.
The 3 sections were separated from each other by mesh
so that C. felis could move amongst the cats, while body
contact between cats or fighting with members of other
groups was prevented. Sections R1 and R3 were adjacent
to the center section R2 but not to each other. Approxi-
mately 25% of the floor space in each section was covered
in carpet to promote survival and a complete life cycle of
C. felis within the room. Cat perches were placed in the
corners of each section adjacent to the mesh dividing the
sections to encourage cats from the various groups to be
close to each other. Based on this design, it seems unlikely
the physical structure itself would influence C. felis to
preferentially transfer to R1 or R3.
The group in R1 (n = 7 cats) were untreated control cats
throughout the study, the group in R2 (n = 4 cats) were
infected with B. henselae by intravenous inoculation of
0.2 ml of blood containing B. henselae strain CSU-1 on
Day – 39 of the study, and the flea and tick collars were
placed on the group in R3 on Day 0 of the study. After
placement of the collars on Day 0, a total of 50 males
and 50 female C. felis were placed on each of the 4 cats
in the B. henselae infected group in R2. Additional fleas
(50 males and 50 female) were placed on each of the R2
cats monthly for an additional 6 applications and then
every 12 – 14 days for 4 applications. The interval
between C. felis application was shortened at the end of
the experiment to increase likelihood of B. henselae
infection in all cats. Flea counts by flea comb were
determined every 12 – 14 days for the duration of the
study and the fleas returned to the cat. The flea collars
were removed from R3 cats on Day 238 of the study, all
cats were administered imidaclopridf once at that time,
and then were observed and sampled as described until
Day 254. Once shown to be negative for B. henselae by
PCR, the cats were returned to the research facility cat
colony with biosafety committee approval.
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spp. serology and PCR assay for amplification of Bartonella
spp. DNA on Days 0, 14, 28, 42, 56, 70, 84, 98, 112, 126,
140, 154, 168, 182, 196, 210, 224, 238, and 252 for all cats
as well as on Days −30, -23, -16, -9 and −2 for cats in R2.
Assays
Blood samples (2 ml in a clot tube for serum separation;
1 ml in EDTA) from each cat were transported from the
research facility to Colorado State University within 2 hours
of collection. Samples were prepared for determination of
serum titers of IgG against Bartonella spp. and for PCR
assay for Bartonella spp. DNA on the day of collection
[12,14]. One aliquot of each blood sample (500 μL) in
EDTA was stored at −80°C for bacterial culture, pending
results of the Bartonella spp. PCR assay. Samples negative
for Bartonella spp. DNA by PCR assay were cultured
using the stored blood as previously described [7]. Results
for samples that yielded characteristic Bartonella spp.
colonies were confirmed by Bartonella spp. PCR assay.
Clinical monitoring
The cats were examined daily for attitude and appetite
throughout the study. Mucous membrane color assess-
ment and physical examination (including cardiac auscul-
tation) was made on any cat exhibiting signs of depression
or inappetance and for cats with a rectal body temperature
of > 102.5°F (39.2°C). Any cat with fever had a complete
blood cell count performed. Cats that developed clinical
illness consistent with bartonellosis (fever and inappetance
of > 2 days duration) during the study were administered
enrofloxacing at 5 mg/kg, PO, daily for at least 14 days
and supportive care as indicated. Cats requiring antibiotic
treatment were administered imidaclopridf and moved to
a C. felis free room for continued care.
Cat hair sampling
On Day 224, approximately 0.5 g of hair was collected
from each cat. Each sample was placed into an individually
labelled plastic bag for determination of imidacloprid
concentrations.h The cutoff sensitivity for the imidacloprid
assay is 0.1 mg/kg hair.
Statistical analysis
Cats were diagnosed with B. henselae infection if at least 2
samples over the course of the study were positive for
Bartonella spp. IgG, Bartonella spp. DNA by PCR assay,
or Bartonella spp. organisms by culture. The proportion of
B. henselae-infected cats was compared between groups R1
and R3 by use of a 2-tailed Fisher exact test. Differences
among group mean flea counts were compared with the
2-tailed Student t test. A value of P < 0.05 was considered
significant for all analyses.Results
Clinical findings
Side-effects associated with the collars were not noted in
any cat throughout the study. While none of the cats in
R2 or R3 developed clinical signs of bartonellosis after
starting the C. felis infestations, 2 cats in R1 developed
clinical signs necessitating treatment. For one cat from
group R1, clinical signs were first detected on Day 47 of
the study; the cat was normal 3 days after starting
enrofloxacin therapy (14 days total) and fluids subcutane-
ously (once). The complete blood cell count for this cat
was normal. The infection status of this cat was monitored
in a separate room for several months. As the cat was still
positive for B. henselae DNA on Day 154 and had only
been administered imidacloprid once, over 100 days previ-
ously, it was returned to R1 to provide a continued source
of B. henselae to attempt maximize the challenge infection
for other cats in R1 and the cats in R3.
One other cat from group R1 developed clinical signs of
bartonellosis on Day 124. Fever, lethargy, and a II/VI
systolic left base heart murmur were the most significant
findings. The complete blood cell count was normal
other than the presence of 200 band neutrophils/μl
(normal = 0 cell/μl) which could suggest inflammation. A
scanning echocardiogram showed normal valve leaflets
and so the cardiac murmur was believed to be from stress.
The cat was negative for Bartonella spp. IgG but positive
for B. henselae DNA by PCR assay on Day 124. The fever
and lethargy resolved over the first 3 days of enrofloxacin
administration (28 days total) and the heart murmur was
not noted on subsequent recheck examinations. The cat
was positive for Bartonella DNA alone on Days 154 and
positive for Bartonella DNA and IgG on Day 168 and Day
182. This cat was not returned to the study.
Assay results
All 4 of the group R2 cats became seropositive and PCR
assay positive after IV inoculation. Bartonella henselae
DNA was amplified from all 4 cats from Day 0 – 28 of
the study. From Day 42 to Day 168, 1 – 3 cats in R2
were PCR positive on any given day. All R2 cats were
PCR negative from Day 182 to Day 252. Each of the R2
cats seroconverted with maximal titers of 64; 128; 512;
and 1028. The first positive antibody test results were
detected on Day 56; Day 154 (2 cats), and Day 168. All 4
R2 cats were still seropositive on Day 252 (titers = 64;
64; 128; 256).
Of the 7 cats in R1 (no treatment), 4 cats had
B. henselae amplified from blood with the first positive
test results being detected on Days 28, 42, 126, and 140
(Figure 1). The first positive antibody test results for R1
cats were detected on Day 56; Day 154 (2 cats), and Day
168. Maximal titers were 64; 128; 512; and 4,096. None
of the PCR negative cats were blood culture positive.
Days after initial C. felis placement 
Cat 0 14 28 42 56 70 84 98 112 126 140 154 168 182 196 210 224 238 252
1 0 0 0 0 0 0 0 0 0 0 0 0 128 128
2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0 0 0 64 64 64 64 0 64 128 64
4 0 0 0 0 64 128 128 512 128 256 256 512 256 256 512 128 256 256 256
5 0 0 0 0 4096 1024 1024 1024 4096 512 512 512
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Figure 1 Bartonella henselae antibody and PCR assay results in 7 untreated cats (R1) exposed to C. felis allowed to feed on cats with B.
henselae infection induced by IV inoculation. Light gray shaded areas indicate samples that were PCR positive; Dark gray areas indicate the
days on which the cats were removed from the room because of fever and need for supportive care; exposure to C. felis began on Day 0. None
of the PCR negative cats were blood culture positive.
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in 4 of 7 of the untreated cats, none of the R3 cats with
collars became infected (P = 0.026).Ctenocephalides felis counts
Most group R2 cats had detectable infestations when
C. felis counts were made over time (Figure 2). However,
the number of C. felis per cat varied on a given day. Only
one C. felis was found on one cat in R3 over the course of
the study (Day 238). The C. felis counts were variable for
the cats in R1 as well. The only day that C. felis counts
were significantly different amongst groups was on Day 14
when cats in R2 had great numbers of C. felis than cats in
R1 or R3.Figure 2 Results (mean and standard deviation) of Ctenocephalides fe
housed in R3 which was adjacent to R1 and R2. The 4 cats in R2 had b
males and 50 female C felis were placed on the R2 cats on Day 0, monthly
applications. There were 6 – 7 cats in R1 over the course of the study. Only
(Day 238). The only day that C. felis counts were significantly different amo
felis than cats in R1 or R3.Cat hair sampling
Imidacloprid could be detected in the hair samples of all
group R3 cats, some of the R1 cats (4 of 6) and some of
the R2 cats (1 of 4). The values varied amongst group R1
(mean = 0.25 mg/kg hair; SD = 0.22; range = 0 – 0.62), R2
(mean = 0.04 mg/kg hair; SD = 0.07; range = 0 – 0.15), and
R3 (mean = 32.4 mg/kg hair; SD = 7.93; range = 17.89 –
41.71).Discussion
In this setting, use of a collar containing 10% imidacloprid
and 4.5% flumethrin was well tolerated and prevented
C. felis transmission of this strain of B. henselae amongst
cats. These results are similar to those achieved in alis counts over time after placement of a flea collar on cats
een experimentally infected with Bartonella henselae and a total of 50
for an additional 6 applications and then every 12 – 14 days for 4
one C. felis was found on one cat in R3 over the course of the study
ngst groups was on Day 14 when cats in R2 had greater numbers of C.
Lappin et al. Parasites & Vectors 2013, 6:26 Page 5 of 6
http://www.parasitesandvectors.com/content/6/1/26previous study using 10% imidacloprid/1% moxidectin
applied topically every month [7]. A potential limitation of
the current study was the relatively low flea burdens on
the cats in R1 detected over the course of the study which
may have lessened the potential for transmission of
B. henselae among the cats in this group. In the previous
study, 100% of the control group developed B. henselae
infection within the 3 month study period in contrast to a
57.1% infection reported here. The relatively low flea
numbers on cats in R1 and R2 may also have lessened the
risk for acquiring B. henselae infection in the cats with
collars in R3.
The previous study of 10% imidacloprid/1% moxidectin
applied topically every month used essentially the same
study design [7]. However, in that study mean C. felis
numbers on the control cats were generally > 2 fleas/cat
after the first 14 days of the study which was numerically
higher than the C. felis numbers reported in the control
cats (R1) described here. Day 14 was the only time of the
study described here that showed statistically higher
C. felis counts in cats housed on R2 when compared to
those in R1 and R3. This finding persisted even when the
C. felis infestations were increased to every 14 days for the
last month of the study. One likely explanation for these
findings is that imidacloprid was shared amongst cats in
the three groups by contact through the mesh walls. This
hypothesis was the reason for collection of hair samples at
day 224 for evaluation of their imidacloprid content. As
imidacloprid is a very efficacious active ingredient, even
low doses could interfere with flea survival on the animals
and via killing flea larvae also interrupt the establishment
of a constant flea population. Imidacloprid values found in
the treated cat’s hair fit to the values detected in pre-
licensing studies (Unpublished Data, 2012). However,
traces of imidacloprid being at up to approximately 1% of
this amount were also detected in the hair samples of
untreated cats from R1 and R2. While only low
concentrations of imidacloprid were detected, this was
likely enough to lessen C. felis numbers, especially by
interfering with the flea development life cycle.
At least one cat was B. henselae infected until Day 210
of the study and so could have served as a source of
B. henselae for the new C. felis added in the later weeks
of the experiment. These results suggest that the collar
prevented B. henselae infection to the cats in R3 for the
entire 8 month study period.
Development of fever and lethargy in 2 of 7 cats (28.5%)
was similar to what was reported in the previous 10%
imidacloprid/1% moxidectin study [7]. The results suggest
that the CSU-1 strain of B. henselae is pathogenic to some
cats and that virulence was not changed by one passage
through cats. As observed in the previous study, the IV
inoculated cats in R2 did not develop clinical illness which
suggests pathogenic factors may be provided by the vector[7]. The two clinically ill cats administered enrofloxacin
had rapid clinical responses suggesting a treatment effect.
However, bacteremia was not eliminated in cats
administered either a 14 day or 28 day course of therapy.
Future research on how to limit B. henselae bacteremia in
cats is needed.
Conclusions
Use of imidacloprid containing products in this model can
block transmission of this strain of B. henselae among
cats. The CSU-1 strain of B. henselae can cause clinical
disease in cats, particularly when vectored by C. felis.
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